Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

Study acronym: CAPSTONE
StatusCompleted
PhasePhase 2
SponsorQian Chu
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Unknown → Completed Show 4 more changesShow less
    • Final enrollment: 17 participants (planned 28)
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised at 8 of 8 sites
  2. Changed Registry marked status Unknown; last known: Recruiting
  3. Primary completion date: Dec 31, 2023 to Dec 30, 2024
    • Study sites: 1 to 8
    • Study completion date: Jun 2024 to Jun 30, 2025
    • Secondary endpoints: 4 to 5
    v4
  4. Primary completion date: Jun 2023 to Dec 31, 2023
    • Study completion date: Dec 2023 to Jun 2024
    v3
  5. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Jun 2022 to Jun 2023
    • Study sites: 0 to 1
    • Study completion date: Jun 2023 to Dec 2023
    • Start date changed from estimate of May 2021 to Jul 19, 2021
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Qian Chu
5 trials monitored
See all monitored trials
Lung Cancer
4,798 trials monitored
See 270 trials at risk
Sarcoma
1,027 trials monitored
See 70 trials at risk
This is a single arm, multi-center clinical trial. Target population is patients with Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma，aiming to evaluate the efficacy and safety of the combination therapy of Camrelizumab and famitinib . Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody, and famitinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor.
Trial Details
NCT Number NCT04888429
Lead Sponsor Qian Chu
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions
(from sponsor)		 Sarcomatoid Carcinoma of Lung
Enrollment 17 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov